3-Dose Malaria Vaccine Demonstrates Safety, Efficacy in West Africa
On January 5th, 2023, an article on Infectious Disease Special Edition, written by Landon Grey, reports on the safety and efficacy demonstrated by Sanaria’s PfSPZ Vaccine in Burkina Faso.
This was a two-part study with part 1 consisting of a dose-escalation trial with 32 participants. Part 2 was a double-blind, randomized, placebo-controlled trial with 80 participants receiving vaccine or saline.
Vaccine efficacy was shown to be 48% at six months (P=0.061) and 46% at 18 months (P=0.018).
“Our study shows that the vaccine can be given to malaria-experienced adults in a highly endemic area and still provide protection, which is difficult and complicated as these individuals already have significant immune responses to malaria parasites that must be overcome by a vaccine for it to be successful,” said Dr. Laurens.
